Abnormal p53 expression is rare in clinically localized human prostate cancer: Comparison between immunohistochemical and molecular detection of p53 mutations
✍ Scribed by Mottaz, Alain E.; Markwalder, Regula; Fey, Martin F.; Klima, Irena; Merz, Vincent W.; Thalmann, George N.; Ball, Roland K.; Studer, Urs E.
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 180 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0270-4137
No coin nor oath required. For personal study only.
✦ Synopsis
BACKGROUND.
We assessed the frequency and molecular basis of p53 mutations in clinically localized prostatic adenocarcinoma. METHODS. Prostate specimens were examined from 100 patients with clinically localized prostatic adenocarcinoma and 13 patients with benign prostatic hyperplasia (BPH). Mutations producing nuclear accumulation of p53 were detected immunohistochemically. Exonspecific mutations were analyzed by polymerase chain reaction amplification and single strand conformation polymorphism (PCR-SSCP) and sequenced. RESULTS. p53 accumulation was detected in 5 tumors using antibody DO-1, and in 4 of these using antibody PAb 1801, but not in BPH. PCR-SSCP detected mutations in all 5 tumors, with alterations in exon 5 for 1 tumor, exon 6 for 3 tumors, and exon 7 for 1 tumor. An exon 6 mutation was also found in a tumor with no anti-p53 staining. CONCLUSIONS. p53 mutations are uncommon in clinically localized prostatic adenocarcinoma and absent from BPH. 5 of the 6 mutations were derived from locally invasive, prostate carcinomas, supporting the hypothesis that mutation of p53 is a late event in prostate carcinoma progression.